OPK - OPKO Health, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.1000
-0.0400 (-1.87%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.1400
Open2.1600
Bid0.0000 x 42300
Ask0.0000 x 38800
Day's Range2.1000 - 2.1800
52 Week Range1.7300 - 6.4000
Volume2,806,320
Avg. Volume4,802,587
Market Cap1.293B
Beta (3Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire16 days ago

    OPKO Health’s BioReference Laboratories Forms a Strategic Collaboration With SOMOS to Improve Health Outcomes of Underserved New Yorkers

    OPKO Health (OPK) announced that its subsidiary, BioReference Laboratories, one of the largest clinical laboratories in the United States, has been selected by SOMOS, a physician-led network of more than 2,500 health care providers serving over 700,000 Medicaid beneficiaries in New York City, as its preferred provider of diagnostic testing and to assist with data analytics for its patients.  This new collaboration is designed to streamline patient care and offer communication efficiencies between BioReference and the SOMOS network. SOMOS is New York City’s largest multi-cultural physician-led network that serves predominately underserved patient populations.

  • GlobeNewswire16 days ago

    BioReference Laboratories Forms a Strategic Collaboration with SOMOS to Improve Health Outcomes of Underserved New Yorkers

    BioReference Laboratories, Inc., an OPKO Health (OPK) company and one of the largest clinical laboratories in the United States, has been selected by SOMOS, a physician-led network of more than 2,500 health care providers serving over 700,000 Medicaid beneficiaries in New York City, as its preferred provider of diagnostic testing and to assist with data analytics for its patients.  This new collaboration is designed to streamline patient care and offer communication efficiencies between BioReference and the SOMOS network.

  • GlobeNewswire19 days ago

    Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test

    OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued a new proposed local coverage determination (LCD) for the 4Kscore® test, with defined coverage criteria.  Under the LCD, Medicare will reimburse the test for patients who meet the defined criteria.  The full text of the updated LCD can be found here.

  • GlobeNewswire27 days ago

    OPKO Health Submits De Novo Request to the U.S. FDA for the 4Kscore® Test

    OPKO Health, Inc. (OPK) announces that the Company has submitted a de novo request to the U.S. Food and Drug Administration (FDA) seeking regulatory clearance for the 4Kscore® test. The 4Kscore® test is a blood test used by health care professionals to assess a patient’s risk of having aggressive prostate cancer after an abnormal prostate specific antigen (PSA) test result, and before a decision is made to perform a biopsy. The de novo pathway for approval is available to medical devices of low-to-moderate risk that do not have an approved predicate device.  Per FDA guidelines, the Company expects to receive a response to this request within approximately 180 days.

  • GlobeNewswirelast month

    BioReference Laboratories Supports Man Cave Health During National Men’s Health Month

    A PSA blood test is standard of care for prostate cancer screening, a critical first step in the identification and diagnosis of prostate cancer, with most national guidelines recommending testing for men between the ages of 45 and 75.  Men in higher risk categories, including African Americans and those with a family history of the disease, should consult with their physicians about screening recommendations.

  • GlobeNewswire2 months ago

    Aerobic Vaginitis (AV) Testing Now Available At BioReference Laboratories

    BioReference Laboratories, Inc., an OPKO Health company, along with its specialty women’s health division, GenPath, today announces the launch of new testing for aerobic vaginitis (AV). AV is a vaginal infection caused by the overgrowth of aerobic bacteria that triggers an inflammatory response.

  • GlobeNewswire2 months ago

    OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results

    MIAMI, May 07, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2019. Business Highlights.

  • GlobeNewswire2 months ago

    BioReference Laboratories to Present at ACOG 2019, Demonstrating Commitment to the Research of Hereditary Conditions

    BioReference Laboratories, Inc., an OPKO Health Company, along with its women’s health division GenPath, today announced the presentation of new research from its prenatal and hereditary cancer assessment programs at the 2019 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in Nashville, Tennessee from May 3-6. The poster presentations demonstrate the company’s commitment to advancing the research of hereditary conditions.

  • GlobeNewswire3 months ago

    OPKO Health to Report First Quarter 2019 Financial Results on May 7, 2019

    MIAMI, April 30, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) plans to report its operating and financial results for the three months ended March 31, 2019, as well as provide.

  • GlobeNewswire3 months ago

    BioReference Laboratories Recognized by Forbes as Best Large Employer of 2019

    BioReference Laboratories, Inc., an OPKO Health Company (OPK), is pleased to announce it has been recognized by Forbes as one of America’s Best Large Employers of 2019. This list includes 500 large companies, and BioReference is one of only 15 companies in the Health Care Equipment and Services category to be selected for this designation. BioReference provides comprehensive laboratory testing to physicians, clinics, hospitals, employers, government entities, correctional institutions and medical groups.

  • GlobeNewswire3 months ago

    OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial

    MIAMI, April 12, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) today reported additional results from the per protocol patient population from the Phase 2 dose escalation trial of.

  • GlobeNewswire4 months ago

    OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial

    MIAMI, March 21, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) today announced positive topline results from a Phase 2 dose escalation trial of OPK88003 to treat type 2 diabetes and.

  • ACCESSWIRE5 months ago

    Watch These Four Healthcare Stocks Set The Pace on Thursday

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aceto Corporation (ACET), OPKO Health Inc (OPK), and Midatech Pharma plc (NASDAQ:MTP) represent 4 healthcare stocks to pay attention to on Thursday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company which is laser-focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies to champion products and services meant to improve the quality of life for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced the launch of at technology-enabled mental health counseling service for patients in urban centers and remote and underserved populations.

  • GlobeNewswire5 months ago

    OPKO Health Reports 2018 Fourth Quarter Business Highlights and Financial Results

    MIAMI, Feb. 27, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2018. Business.

  • GlobeNewswire5 months ago

    OPKO Health to Announce Fourth Quarter 2018 Financial Results on February 27, 2019

    OPKO Health, Inc. (OPK) plans to announce its operating and financial results for the three and twelve months ended December 31, 2018 as well as provide guidance on expected revenues and operating expenses for the first quarter 2019 after the close of the U.S. financial markets on Wednesday, February 27, 2019. OPKO’s senior management will provide a business update and discuss its financial results in a live conference call and audio webcast beginning at 4:30 p.m. Eastern time on Wednesday, February 27, 2019. OPKO’s senior management will provide a business update and discuss results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time on Wednesday, February 27, 2019.

  • GlobeNewswire5 months ago

    Research Report Identifies Cognizant Technology Solutions, OPKO Health, MedEquities Realty Trust, AXT, Red Robin Gourmet Burgers, and Dorian LPG with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • GlobeNewswire5 months ago

    OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes

    OPKO Health, Inc. (“OPKO Health” or the “Company”) (OPK) today announced the pricing of its offering of $200 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”). The Notes will be general senior unsecured obligations of the Company, will pay interest semiannually in arrears at a rate of 4.50% per annum, and will mature on February 15, 2025, unless earlier repurchased, redeemed or converted. The Notes will be convertible into, at the Company’s election, cash, shares of the Company’s common stock, or a combination of cash and common stock, as further described in the prospectus supplement.

  • PR Newswire5 months ago

    Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm

    SAN DIEGO , Feb. 5, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies: AbbVie Inc. (NYSE: ABBV) [click here to join ...

  • GlobeNewswire5 months ago

    OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes

    OPKO Health, Inc. (“OPKO Health” or the “Company”) (OPK) today announced that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”) in an underwritten public offering. The Notes will be general senior unsecured obligations of the Company, will pay interest semiannually in arrears and will be convertible into, at the Company’s election, cash, shares of the Company’s common stock, or a combination of cash and common stock, as further described in the prospectus supplement.

  • GlobeNewswire5 months ago

    OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer

    MIAMI, Feb. 01, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s point-of-care Sangia Total.

  • GlobeNewswire5 months ago

    OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator

    OPKO Health, Inc. (OPK) today announced an update on the ongoing development plans of OPK-88004, a selective androgen receptor modulator (SARM). OPK-88004 has the ability to serve as an antagonist to androgen receptors in the prostate, resulting in decreased prostate specific antigen (PSA) levels, and as an agonist resulting in increased anabolic effects, such as increased lean body mass and physical function and decreased fat mass.

  • GlobeNewswire5 months ago

    Future Non-Coverage Determination for 4Kscore Test Posted by Novitas

    OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued a notice of a future non-coverage determination for the 4Kscore test® to be effective March 20, 2019. The notice released by Novitas today does not appear to be different from the draft local coverage determination released by Novitas on May 18, 2018. OPKO is evaluating options to appeal the decision and undertake other steps with the U.S. Centers for Medicare & Medicaid Services (CMS) in an effort to have this determination rescinded or reversed.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: OPKO Health and Endo International

    NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...

  • GlobeNewswire6 months ago

    BioReference Laboratories Supports Federal Employees Amidst Government Shutdown

    BioReference Laboratories Inc., an OPKO Health Company (OPK), today announced that they will offer flexible payment arrangements for federal employees affected by the government shutdown. “We recognize the challenging financial position that federal government employees have faced throughout the shutdown,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. BioReference and its divisions, GenPath Diagnostics and GeneDx, developed a program to defer laboratory payments for 30 days to furloughed federal government employees.

  • ACCESSWIRE6 months ago

    4 Healthcare Stocks Setting The Pace On Monday (1/14/19)

    CORAL GABLES, FL / ACCESSWIRE / January 14, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Microbot Medical Inc (MBOT), Valeritas Holdings Inc (VLRX), and Opko Health Inc (OPK) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.